Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 115

1.

APRIL, a proliferation-inducing ligand, as a potential marker of lupus nephritis.

Treamtrakanpon W, Tantivitayakul P, Benjachat T, Somparn P, Kittikowit W, Eiam-ong S, Leelahavanichkul A, Hirankarn N, Avihingsanon Y.

Arthritis Res Ther. 2012 Nov 21;14(6):R252. doi: 10.1186/ar4095.

2.
3.

Intrarenal production of B-cell survival factors in human lupus nephritis.

Neusser MA, Lindenmeyer MT, Edenhofer I, Gaiser S, Kretzler M, Regele H, Segerer S, Cohen CD.

Mod Pathol. 2011 Jan;24(1):98-107. doi: 10.1038/modpathol.2010.184. Epub 2010 Oct 1.

4.

Urinary B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL): potential biomarkers of active lupus nephritis.

Phatak S, Chaurasia S, Mishra SK, Gupta R, Agrawal V, Aggarwal A, Misra R.

Clin Exp Immunol. 2017 Mar;187(3):376-382. doi: 10.1111/cei.12894. Epub 2016 Dec 5.

PMID:
27804111
5.

Serum levels of tumour necrosis factor family members a proliferation-inducing ligand (APRIL) and B lymphocyte stimulator (BLyS) are inversely correlated in systemic lupus erythematosus.

Morel J, Roubille C, Planelles L, Rocha C, Fernandez L, Lukas C, Hahne M, Combe B.

Ann Rheum Dis. 2009 Jun;68(6):997-1002. doi: 10.1136/ard.2008.090928. Epub 2008 Aug 2.

PMID:
18676986
6.

Expressions of BAFF/BAFF receptors and their correlation with disease activity in Chinese SLE patients.

Zhao LD, Li Y, Smith MF Jr, Wang JS, Zhang W, Tang FL, Tian XP, Wang HY, Zhang FC, Ba DN, He W, Zhang X.

Lupus. 2010 Nov;19(13):1534-49. doi: 10.1177/0961203310375268.

PMID:
20974656
7.

Treatment for lupus nephritis.

Henderson L, Masson P, Craig JC, Flanc RS, Roberts MA, Strippoli GF, Webster AC.

Cochrane Database Syst Rev. 2012 Dec 12;12:CD002922. doi: 10.1002/14651858.CD002922.pub3. Review.

PMID:
23235592
8.

Evaluation of B lymphocyte stimulator and a proliferation inducing ligand as candidate biomarkers in lupus nephritis based on clinical and histopathological outcome following induction therapy.

Parodis I, Zickert A, Sundelin B, Axelsson M, Gerhardsson J, Svenungsson E, Malmström V, Gunnarsson I.

Lupus Sci Med. 2015 Jan 22;2(1):e000061. doi: 10.1136/lupus-2014-000061. eCollection 2015. Erratum in: Lupus Sci Med. 2015;2(1). pii: lupus-2014-000061corr1. doi: 10.1136/lupus-2014-000061corr1.

9.

Identification of biomarkers that predict response to treatment of lupus nephritis with mycophenolate mofetil or pulse cyclophosphamide.

Dall'Era M, Stone D, Levesque V, Cisternas M, Wofsy D.

Arthritis Care Res (Hoboken). 2011 Mar;63(3):351-7. doi: 10.1002/acr.20397. Epub 2010 Nov 15.

10.

To target or not to target APRIL in systemic lupus erythematosus: that is the question!

Morel J, Hahne M.

Arthritis Res Ther. 2013 Feb 25;15(1):107. doi: 10.1186/ar4160.

11.

Dual blockade of the pro-inflammatory chemokine CCL2 and the homeostatic chemokine CXCL12 is as effective as high dose cyclophosphamide in murine proliferative lupus nephritis.

Devarapu SK, Kumar Vr S, Rupanagudi KV, Kulkarni OP, Eulberg D, Klussmann S, Anders HJ.

Clin Immunol. 2016 Aug;169:139-147. doi: 10.1016/j.clim.2016.07.003. Epub 2016 Jul 5.

PMID:
27392463
12.

[Treatment of lupus nephritis].

Novak S.

Lijec Vjesn. 2014 Jul-Aug;136(7-8):215-9. Review. Croatian.

PMID:
25327009
13.

The prognosis of biopsy-proven lupus nephritis in chinese patients: long term follow-up of 86 cases.

Shen K, Yu Y, Tang Z, Liu Z, Li L.

Chin Med J (Engl). 1997 Jul;110(7):502-7.

PMID:
9594205
14.

Mycophenolate mofetil as maintenance therapy for childhood-onset systemic lupus erythematosus patients with severe lupus nephritis.

Kizawa T, Nozawa T, Kikuchi M, Nagahama K, Okudela K, Miyamae T, Imagawa T, Nakamura T, Mori M, Yokota S, Tsutsumi H.

Mod Rheumatol. 2015 Mar;25(2):210-4. doi: 10.3109/14397595.2014.950810. Epub 2014 Aug 27.

PMID:
25159157
15.

B-lymphocyte stimulator/a proliferation-inducing ligand heterotrimers are elevated in the sera of patients with autoimmune disease and are neutralized by atacicept and B-cell maturation antigen-immunoglobulin.

Dillon SR, Harder B, Lewis KB, Moore MD, Liu H, Bukowski TR, Hamacher NB, Lantry MM, Maurer M, Krejsa CM, Ellsworth JL, Pederson S, Elkon KB, Wener MH, Dall'Era M, Gross JA.

Arthritis Res Ther. 2010;12(2):R48. doi: 10.1186/ar2959. Epub 2010 Mar 19.

16.

[Significance of serum anti-Clq Ab in evaluation of lupus nephritis activity and its curative effects of pharmacotherapy on lupus nephritis].

Cai XY, Yang XY, Chen XH, Liang LQ, Guan MM, Qin SG, Fu JZ.

Zhonghua Yi Xue Za Zhi. 2004 Sep 2;84(17):1436-9. Chinese.

PMID:
15500738
17.

Post Hoc Analysis of the Phase II/III APRIL-SLE Study: Association Between Response to Atacicept and Serum Biomarkers Including BLyS and APRIL.

Gordon C, Wofsy D, Wax S, Li Y, Pena Rossi C, Isenberg D.

Arthritis Rheumatol. 2017 Jan;69(1):122-130. doi: 10.1002/art.39809. Epub 2016 Dec 2.

18.

Induction therapy for active lupus nephritis: mycophenolate mofetil versus cyclophosphamide.

Burchardi C, Schlöndorff D.

Nat Clin Pract Nephrol. 2006 Jun;2(6):314-5. No abstract available.

PMID:
16932452
19.

Serum BAFF predicts prognosis better than APRIL in diffuse large B-cell lymphoma patients treated with rituximab plus CHOP chemotherapy.

Kim SJ, Lee SJ, Choi IY, Park Y, Choi CW, Kim IS, Yu W, Hwang HS, Kim BS.

Eur J Haematol. 2008 Sep;81(3):177-84. doi: 10.1111/j.1600-0609.2008.01099.x. Epub 2008 May 27.

PMID:
18510703
20.

Differential effects on BAFF and APRIL levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritis.

Vallerskog T, Heimbürger M, Gunnarsson I, Zhou W, Wahren-Herlenius M, Trollmo C, Malmström V.

Arthritis Res Ther. 2006;8(6):R167.

Supplemental Content

Support Center